A threshold for mitotic activity and post‐surgical residual volume defines distinct prognostic groups for astrocytoma IDH‐mutant

Archive ouverte

Tran, Suzanne | Thomas, Alice | Aliouat, Ilyes | Karachi, Carine | Lozano, Fernando | Mokhtari, Karima | Dehais, Caroline | Feuvret, Loïc | Carpentier, Catherine | Giry, Marine | Doukani, Abiba | Lerond, Julie | Marie, Yannick | Sanson, Marc | Idbaih, Ahmed | Carpentier, Alexandre | Hoang-Xuan, Khê | Touat, Mehdi | Capelle, Laurent | Bielle, Franck

Edité par CCSD ; Wiley -

International audience. Aims The distinction between CNS WHO grade 2 and grade 3 is instrumental in choosing between observational follow‐up and adjuvant treatment for resected astrocytomas IDH‐mutant. However, the criteria of CNS WHO grade 2 vs 3 have not been updated since the pre‐IDH era. Methods Maximal mitotic activity in consecutive high‐power fields corresponding to 3 mm 2 was examined for 118 lower‐grade astrocytomas IDH‐mutant. The prognostic value for time‐to‐treatment (TTT) and overall survival (OS) of mitotic activity and other putative prognostic factors (including age, performance status, pre‐surgical tumour volume, multilobar involvement, post‐surgical residual tumour volume and midline involvement) was assessed for tumours with ATRX loss and the absence of CDKN2A homozygous deletion or CDK4 amplification, contrast enhancement, histological necrosis and microvascular proliferation. Results Seventy‐one per cent of the samples had <6 mitoses per 3 mm 2 . Mitotic activity, residual volume and multilobar involvement were independent prognostic factors of TTT. The threshold of ≥6 mitoses per 3 mm 2 identified patients with a shorter TTT (median 18.5 months). A residual volume ≥1 cm 3 also identified patients with a shorter TTT (median 24.5 months). The group defined by <6 mitoses per 3 mm 2 and a residual volume <1 cm 3 had the longest TTT (median 73 months) and OS (100% survival at 7 years). These findings were confirmed in a validation cohort of 52 tumours. Conclusions Mitotic activity and post‐surgical residual volume can be combined to evaluate the prognosis for patients with resected astrocytomas IDH‐mutant. Patients with <6 mitoses per 3 mm 2 and a residual volume <1 cm 3 were the best candidates for observational follow‐up.

Consulter en ligne

Suggestions

Du même auteur

Initial surgical resection and long time to occurrence from initial diagnosis are independent prognostic factors in resected recurrent IDH wild-type glioblastoma

Archive ouverte | Seyve, Antoine | CCSD

International audience. Objective: IDH wild-type glioblastoma is the most common and aggressive primary brain cancer in adults. At tumor recurrence, treatment decision-making is not standardized; several options inc...

Survival outcomes associated with first-line procarbazine, CCNU, and Vincristine or Temozolomide in combination with radiotherapy in IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma

Archive ouverte | Kacimi, Salah Eddine O. | CCSD

International audience. Purpose: Patients with IDH-mutant 1p/19q-codeleted grade 3 oligodendroglioma (O3IDHmt/Codel) benefit from adding alkylating agent chemotherapy to radiotherapy (RT). However, the optimal chemo...

Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma

Archive ouverte | Benusiglio, Patrick, R | CCSD

International audience. PURPOSE The Lynch syndrome (LS)-glioma association is poorly documented. As for mismatch repair deficiency (MMRd) in glioma, a hallmark of LS-associated tumors, there are only limited data av...

Chargement des enrichissements...